Abstract
tected, which demonstrates that plants are eligible candidates for production of recombinant therapeutics with fully humanized O-and N-glycans.

Conclusion: Plants and methods of plant molecular farming offer a powerful expression platform for the production of a variety of recombinant proteins, which show similar, or even higher, biological activity then protein or native homologs in cultured mammalian cells currently used for largescale production.
IntroductIon R ecombinant DNA technology has allowed expression of different heterologous proteins in many host systems, ranging from prokaryotic to eukaryotic organisms. Recombinant microbial systems (mainly bacteria Escherichia coli) are in use for the last 30 years and they are now very important source of industrial and medicinal proteins (1, 2, 3) . Yet, some classes of proteins cannot be produced in microbial systems due to low product quality, particularly if post-translational processing is needed for stability and activity of proteins. Thus, yeast cells, insect cell lines and mammalian cell cultures have been utilized for eukaryotic protein production (4, 5) , although the implementation of each of these expression systems has its shortcomings (6, 7) . Interestingly, these conventional expression systems typically do not address the problem of glycan heterogeneity albeit they result with products that contain a mixture of glycoforms that are neither identical to human glycans nor optimized for enhanced biological activity (8) .
Over the last decade plants have been developed as recombinant protein production systems in a methodology called plant molecular farming (9) . This methodology exploits transgenic plants and plant cell cultures as production systems for recombinant proteins with commercial, industrial or pharmaceutical applications. Compared to conventional expression systems plant molecular farming has many advantages. Production costs are significantly lower than those of cell-based production systems (10, 11) and plants are capable of performing eukaryotic-like post-translational modifications (PTMs) (12, 13) , which allow the production of recombinant humanized molecules that are highly similar or even identical to the native protein (14, 15) . In addition, engineering of plant expression systems enables the production of recombinant proteins with specific and controlled modifications, which provide additional benefit for plant-made products that cannot be replicated in bacterial or yeast expression systems (6, 16, 17) . Plants are particularly well suited for production of therapeutic recombinant products such as antibodies and vaccines (18, 19) , since generally they do not carry human pathogens that can be associated with mammalian expression systems.
The main limitations of plant expression systems are differences in the glycosylation pathway, namely complex processing of glycan side-chains, including some hostspecific modifications that do not occur in humans and vice versa (20, 21, 22) . These imperfections can partly be overpowered by glycoengineering, whose goal is production of recombinant proteins with highly homogenous glycosylation that closely resembles the native system. The aim of this paper is to review the accomplishments of the attempts in production of plant-derived glycoconjugates with humanized N-and O-glycans with the emphasis on several approaches: (i) use of C-terminal endoplasmic reticulum (ER) retention motif to prevent formation of plant-specific complex N-glycans and/or O-glycans; (ii) inactivation of plant-specific glycosyltransferases; and (iii) introduction of human-specific glycosyltransferases to obtain humanized N-or O-glycans.
overvIew of post-translatIonal modIfIcatIon of plant proteIns
Glycosylation is the best-studied PTM of plant-made recombinant proteins but other types of protein processing and modification also co-occur and are important in production of high-quality recombinant proteins. After translation, the majority of plant proteins experience covalent modifications that change their tertiary and quaternary structures. PTMs are known to affect almost every aspect of protein activity, from protein function, localization, stability to interaction dynamics with other molecules (23). These modifications are very diverse, and they range from very simple chemical changes, such as the addition of small phosphate or acetate functional groups, to complex changes that are enormous in size and by mass exceed protein part (e.g. proteoglycans) (24, 25). A single type of modification or various combinations of PTMs can modify one protein. These modifications may be influenced by developmental stage, location or by some biotic or abiotic factors, mainly by stress and disease state of a plant (23). In all this cases, PTMs are highly regulated and specific to cellular requirements. In addition, some PTMs (cleavage of a signal peptide or glycosylation) are permanent changes of a protein structure, unlike others (phosphorylation) that are rapidly reversed. The relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation (26). To conclude, PTMs represent mechanism for exponential diversification of a genome and act to extend the repertoire of proteins available to facilitate the complex interactions of proteins in multiple cellular pathways (23).
n-glycosylatIon differences of n-glycosylation between humans and plants Glycosylation is a very prominent PTM in all eukaryotic cells. It is estimated that at least 50% and as high as 70% of human proteins are glycosylated (27). Moreover, 40% of the currently approved protein therapeutics as well as many other clinically useful proteins are glycosylated (28). In N-glycosylation, complex glycan chains are covalently attached to the amide nitrogen in the side chain of asparagine (Asn) residues on newly synthesized proteins. This modification strongly influences many properties of proteins, including folding, self-association, resistance to proteolytic degradation, solubility, protein sorting within the cell, volume and charge of glycoproteins and all that can be important for efficiency of ligand binding and conformational stability or protein half-life (29). Thus, the ability of recombinant expression systems to efficiently and accurately glycosylate proteins is vital to the production of efficient recombinant protein that will be used in clinical applications.
The N-glycosylation pathway in plants is highly homologous with other eukaryotic systems, including the site-occupancy, frequency of glycosylation and the structure and composition of the core high-mannose type glycan added in the ER (23). Glycosylation pathway starts when the core glycan structure is assembled in the ER as a mannose (Man)-rich lipid precursor, Glc 3 Man- 9 GlcNAc 2 , which is transferred by oligosaccharyltransferase complex to the Asn residue in the N-glycosylation consensus sequence Asn-X-Ser⁄ Thr (where X is any amino acid except Pro) (30, 31) . Common N-glycan core structure Man 3 GlcNAc 2 is composed of N,N'-diacetylglucosamine dimmer (GlcNAc-GlcNAc) called chitobiose, a b-Man residue attached to the chitobiose and two aMan residues linked to hydroxyl 3 and 6 of the b-Man (32, 33). Once transferred onto the nascent protein and while the glycoprotein is transported along the secretory pathway, the N-glycan undergoes several maturation steps. The first step includes the removal of three glucose (Glc) residues in ER (34) to generate high-mannose type N-glycans that are common to human, animals and plants (33). Trimming of Man residues occurs after the glycoprotein is transported to Golgi apparatus (GA), which yields oligomannose glycan structures (35). These structures are further extended with GlcNAc residues to form a base for complex-type N-glycans (36). These Nglycans differ between humans and plants ( Figure 1 ), as will be described below. (1, 2) -Xyl additions to allergic reactions in humans are not so straightforward and they are still a matter of debate because of regular exposure to plant materials (in this case specific glycans) in our diets and environment; therefore, the potential of allergenicity in humans may be low. However, there are some findings which suggest that typical plant glycoepitopes may induce rapid clearance from circulation and cause a strong allergic reaction because of the presence of IgE antibodies directed against these epitopes (22, 36) . Even the mouseproduced monoclonal antibody (mAb) in clinical use, Cetuximab, can trigger anaphylactic reactions in atopic patients by producing IgE antibodies against non-primate N-glycans (galactose-a-1,3-galactose) present on the Cetuximab heavy chain (39). Furthermore, mammals have some specific modifications on N-glycans, which do not occur in plants, such as addition of b (1, 4) -galactose (Gal) (40). This limitation can be problematic for production of antibodies since these Gal residues facilitates complement-dependent cytotoxicity and complement binding (41). In addition, plants lack homologs of mammalian N-acetylglucosaminyltransferase (GnT) -III, -IV and -V (11), which are involved in the addition of GlcNAc residues to create branched N-glycans. As a result, plant Nglycans carry only two antenna structures, while mammalian N-glycans commonly contain multi-antennary glycans with two or more terminal branches (42). These multi-antennary structures are important for increasing the serum half-life of recombinant proteins (11) . In plant proteins complex bi-antennary N-glycans have been identified; however, they contain one or two terminal antennae of a (1, 4) Another major drawback of plant N-glycosylation is the lack of sialic (neuraminic) acid (Neu5Ac) on the termini of complex N-glycans, although synthesis of Neu5Ac has been documented in some plant species (46, 47). Nonexistence of this modification presents an obstacle because addition of Neu5Ac is common in mammalian systems and it is known to be important in preventing clearance of recombinant therapeutic proteins (48). 
. Differences in O-glycan structures between human and plant cells: a) Eight known core structures of mucin-type O-glycans, the most abundant class of O-glycosylated proteins in human cells, b) Structures of O-glycans added to Hyp in Hyp-rich glycoproteins (HGRPs), the most abundant and plant-specific class of O-glycosylated proteins. Extensins and arabinogalactan proteins (AGPs) are the most common members of this group.
of the core structure Man 3 GlcNAc 2 . This plant-specific glycans are called paucimannosidic N-glycans, and are commonly found in plant vacuoles (36). In conclusion, plant N-glycans can be classified in four groups: highmannose type, complex type, hybrid type and paucimannosidic type N-glycans (for review see Balen and KrsnikRasol 2007(33)).
modifying n-glycosylation by glycoengineering
Main goal of glycoengineering in the field of molecular farming is to reduce or eliminate plant-specific Nglycans, and at the same time to introduce mammalianspecific N-glycans. One of the key advantages of plant-specific expression systems is that plants are very tolerant to glycoengineering (23). However, it is important to note that in contrast to the N-glycan profile of mammalian cell-derived recombinant proteins, where a mixture of N-glycans is present, the plant-produced counterparts exhibit generally a largely homogeneous glycosylation profile with a single dominant N-glycan species (6, 49, 50) . Recombinant proteins that are secreted by plant cells typically carry two types of N-glycans, complex or paucimannosidic type, and glycosylation profile cannot be predicted in advance. Nevertheless, it is known that two factors that can affect this process are (i) final destination of accumulation and route along the secretory pathway and (ii) intrinsic character of the recombinant protein (23). Currently, the mechanisms and effects of both factors are poorly understood and some examples of current knowledge are shown later in the text.
The easiest way is to change intracellular targeting of plant-made recombinant proteins. This was initially used to increase yields of target proteins but, as we mentioned previously, it may also have an effect on the glycosylation state of the protein. The most common approach for ex- 
Schematic presentation of the humanized N-and O-glycosylation pathways in GA of N. benthamiana ΔXF plants obtained by glycoengineering (modified from Strasser (8)). Expression of mammalian N-acetylglucosaminyltransferase IV (GnTIV) and N-acetylglucosaminyltransferase V (GnTV) is essential for building-up of the multi-antennary complex N-glycans (these enzymes are illustrated in blue). Heterologous expressed enzymes for the formation of disialylated O-glycans are UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), N-acetylneuraminic acid phosphate synthase (NANS), CMP-N-acetylneuraminic acid synthetase (CMAS) and CMP-Neu5Ac transporter (CST) (these enzymes are illustrated in red). For sialylation of complex N-glycans two additional mammalian glycosyltransferases, b1,4-galactosyltransferase (GalT) and a2,6-sialyltransferase (ST), are required (these enzymes are illustrated in blue). Enzymes illustrated in black represent endogenous plant glycosidases and glycoslytransferases that are involved in reactions of early N-glycan modification, Golgi-a-mannosidase I (MNS1/2), N-acetylglucosaminyltransferase I (GnTI), Golgi-a-mannosidase II (GMII) and N-acetylglucosaminyltransferase II (GnTII), as well as enzymes required for conversion and transport of nucleotide sugars for formation of O-and N-glycans, (UDP-GlcNAc 4 epimerase, UDP-GalNAc transporter and Neu5Ac-9-phosphate phosphatase (NANP)).
pression of recombinant proteins in plants is their retention in the ER by addition of C-terminal retention/retrieval signals (H/KDEL) (51,52) or its extended version (e.g. SEKDEL) (53). Protein retention in ER avoids plantspecific N-glycan maturation (a(1,3)-Fuc and/or b(1,2)-Xyl addition) and results in formation of only high-mannose type N-glycans. For example, when recombinant antibody light and heavy chains, produced in transgenic tobacco, were tagged with KDEL sequence they contained exclusively high-mannose N-glycans (54, 55). Moreover, Loos et al. reported that a KDEL-tagged anti-HIV antibody (2G12) was deposited in protein storage vacuoles that bypass the GA carrying mainly high-mannose N-glycans (56), while Triguero et al. showed that plant-derived mouse IgG mAb, fused to KDEL ER-retention signal, was N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans (57). Therefore, plant-specific modifications are reduced, consequently reducing induction of allergic reaction. The drawback of this procedure is that protein is susceptible to increased clearance rates and consequently decreased serum half-life (58). Additionally, some studies suggest that fusion of KDEL sequence to the recombinant glycotherapeutic does not always sufficiently reduce plantspecific N-glycans and the process is dependent on the nature of the recombinant protein (36). He et al. showed that when the human enzyme a-L-iduronidase (IDUA) was expressed with C-terminal ER-retention sequence (SEKDEL) in Arabidopsis thaliana plants, only a moderate proportion of the recombinant protein was retained in ER and decorated with high mannose N-glycans; the remaining fractions were directed to protein storage vacuoles and contained complex/hybrid type, thus suggesting protein transit through the GA (53). Expression of IDUA with the same ER-retention signal in Brassica napus and tobacco seeds showed that the presence of the SEKDEL sequence greatly diminished the molar ratio of typical plant glycoepitopes, Xyl and Fuc (59). These somewhat contradictory results indicate that the extent of the ERretention of a recombinant protein varies also on the plant species and on the type of cell or tissues used as an expression system (60). Moreover, N-glycosylation pattern of the same plant protein is clearly dependent on the level of plant tissue organization and can be related to the specific developmental status (45, 61, 62), while oligosaccharide structures of glycoproteins were found be important determinants of plant tissue morphology (63), which indicates that protein trafficking seems to be changing during the plant development (64, 65). Therefore, this approach for the production of therapeutic proteins appears very unpredictable.
Targeting of recombinant proteins to other intracellular locations, such as GA, oil bodies, chloroplasts, protein storage bodies or vacuole can also have an effect on the degree and type of N-glycosylation, which can be important for protein function and/or stability (66). For example, N-glycans of paucimannosidic type are often regarded as the most typical for vacuoles, but analysis of proteins that are deposited in vacuoles revealed the possibility of complex and high-mannose types as well. Interestingly, paucimannosidic N-glycans are needed for in vivo efficiency of glucocerebrosidase (GCD), enzyme used in the replacement therapy to cure Gaucher disease. When GCD enzyme was fused with C-terminal vacuolar targeting signal, a recombinant enzyme that carried paucimannosidic N-glycans was produced in transgenic carrot cells (15) and it exhibited enhanced in vivo efficiency compared with currently available drug Cerezyme ® produced in Chinese hamster ovary (CHO) cells (67,68). Targeting to the vacuole in these glycoengineered cells resulted in more than 90% of its N-glycans being terminated with Man residues (15) . This is very important since Man endings are necessary for the biological uptake of GCD by macrophages, whose lysosomes are deficient for this enzyme in patients treated for Gaucher disease. Food and Drug Administration (FDA) has approved this carrotproduced enzyme, also known as Elelyso™ in March 2012 for treatment of Gaucher disease in humans and is commercially available in the United States (69). This work is obviously a milestone in industrial production of plantmade recombinant proteins since it is the first and at the moment the only recombinant plant-derived human therapeutic protein approved on the market. (14) . The resultant mAbs contained a single major N-glycan species without detectable plantspecific N-glycans and had better antibody-dependent cell-mediated cytotoxicity and effector cell receptor binding activities than mAbs expressed in cultured CHO cells. In addition to a(1,3)-Fuc and b(1,2) -Xyl epitopes, many plant species display a (1,4)-Fuc and b(1,3) a(1,3)-Fuc and b(1,2) -Xyl residues (44,71,72), they were still detected in recombinant human erythropoietin (hEPO) expressed in both moss (73) a(1,3)-Fuc and b(1,2) -Xyl. However, targeting of Gal-T in different GA compartments can significantly change N-glycosylation of recombinant proteins (83). Namely, incomplete N-glycan processing was reported when human Gal-T were targeted to early/medial GA (80, 82), while the amount of galactosylated structures significantly increased when the Gal-T was directed to trans GA compartments (84) .
Successful attempts of in planta addition of b(1,4)-Gal
to N-glycans represent a step toward terminal sialylation of plant made glycoproteins, since b(1,4)-Gal residues serve as the acceptor substrate for Neu5Ac. This negatively charged sugar affects the biological activities and half-lives of many therapeutic glycoproteins (85, 86) . Although sialic acid was detected in some plant species free or protein-bound (46, 47, 87), the first attempts to facilitate sialylation of endogenous or recombinant proteins in plants were unsuccessful. The reason for that was the fact that plants contain negligible amounts of Neu5Ac and its activated form, cytidinemonophospho-N-acetylneuraminic acid (CMP-Neu5Ac) (88, 89) , which is being transferred to a b(1,4)-Gal-terminus of the complex Nglycan. Castilho et al. performed simultaneous expression in A. thaliana plants of three enzymes required for the synthesis of CMP-Neu5Ac in mammals: mouseUDPGlcNAc 2-epimerase/N-acetylmannosamine kinase (GNE), human N-acetylneuraminic acid phosphatesynthase (NANS), and human CMP-sialic acid synthetase (CMAS), which resulted in the generation of significant amounts of Neu5Ac and CMP-Neu5Ac (90) . Furthermore, six enzymes from the mammalian biosynthetic pathway are necessary to achieve substrate biosynthesis, nucleotide sugar activation, transport and Neu5Ac transfer to N-glycans in planta (17). Therefore, six mammalian proteins comprising the sialic acid pathway (GNE, NANS, CMAS, CMP-Neu5Ac transporter (CST) and 2,6-sialyltransferase (ST-Gal)) were co-expressed together with a mAb in N. benthamiana ΔXT/FT transgenic line. Nearly all of the available acceptor substrates (i.e. galactosylated glycans), present in the glycosylation mutants, were sialylated on the Fc domain of the antibody. It was shown that sialylated 2G12 exhibits similar in vitro HIV neutralization potency to other glycoforms derived from plants and CHO cells, demonstrating full integrity of the protein (17). Moreover, functionally active sialylated hEPO was expressed in N. benthamiana plants (91) .
Finally, in planta generation of biantennary and multiantennary structures on complex N-glycans has also been achieved. The goal was to express the human N-acetylglucosaminyltransferase genes, mainly b1,4-mannosyl-b1,4-N-acetylglucosaminyltransferase (GnT-III) enzyme that is responsible for the addition of bisecting GlcNAc residues to central Man of the core structure, thus creating antennary glycan structures. Additionally, it was important to express a1,3-mannosyl-b1,4-N-acetylglucosaminyltransferase (GnT-IV) and a1,6-mannosyl-b1,6-Nacetylglucosaminyltransferase (GnT-V) that also transfer GlcNAc residues to Man, but the resulting structures are tri-and tetra-antennary N-glycans. Nagels et al. reported production of complex multiantennary N-glycans of endogenous proteins after introduction of GnT-IVa, -IVb and -Va in ΔXT/FT N. benthamiana plants, lacking plantspecific N-glycosylation (11) . In the following work, GnT-III, -IV and -V were co-expressed in ΔXT/FT N. benthamiana plants with the recombinant hEPO and human transferrin (hTF) (6) . This approach resulted in the efficient generation of bisected tetraantennary complex Nglycans without typical plant glycoepitopes on both hEPO and hTF, thus demonstrating generation of recombinant proteins with human-type N-glycosylation at great uniformity.
o-glycosylatIon differences of o-glycosylation between humans and plants
Linkages in which the sugar is attached to an amino acid containing a hydroxyl group occur in great variety of proteins (92) . Therefore, every amino acid with a hydroxyl functional group, serine (Ser), threonine (Thr), tyrosine (Tyr), hydroxylysine (Hyl) or hydroxyproline (Hyp) can be O-glycosylated. O-glycosylation is one of the most complex regulated PTMs, which, dependent on the size and composition of O-glycans, might affect protein conformation and activity (93) . In mammals, O-glycosylation is a common post-translational modification of secreted and membrane-bound proteins (94) and it is fundamentally different from N-glycosylation, as a typical consensus amino acid sequence has not been clearly identified yet (95) . However, O-glycosylation can influence protein function and structure equally as the Nglycosylation (29). In addition, process is highly regulated and varies depending on tissue type and cell state (96, 97) . O-glycosylation has been shown to contribute many biological processes in mammals such as inflammation, coagulation, cancer and viral infections. For example, the presence of O-glycans can mask recognition sites for receptors and other interacting proteins or protect them from degradation by proteases (98) .
O-glycosylation in humans and plants are significantly different processes, and differences include sites of glycan addition, structure and composition of glycans (Figure 2) . In mammals, the most common O-glycosylation sites are Ser and Thr residues decorated with either one sugar molecule such as N-acetylgalactosamine (GalNAc), Fuc, and Gal, or several sugars linked to GalNAc attached to Ser/Thr residues. The most abundant class of O-glycoslyated proteins are the mucin-type glycoproteins. The highly conserved process of mucin-type glycosylation starts with the addition of GalNAc onto the hydroxyl groups of Ser or Thr, which is performed by enzymes from a multigene family known as N-acetylgalactosaminyltransferases (GalNAc-Ts) located in GA. Unlike co-translational and one-step addition of oligosaccharide precursor on Asn residue in N-glycoslation, in O-glycoslyation additional sugars are added step by step post-translationaly by incorporation of Gal, Fuc, GlcNAc and NeuAc residues in different linkages (99) . This process results with complex heterogeneous O-glycans that are classified according to the structure of the glycan core (36), as illustrated in Figure 2A . In principal, plants do not perform GalNAc O-glycosylation (42, 95, 100) . Mammalian mucin-type O-glycans have been reported only for rice glutelin (101) and prolamines (102) . In plants, O-glycans are commonly attached to hydroxyl group of Ser residues (Solenaceous lectin-type glycosylation), Hyp residues, and rarely Thr residues. Hydroxylation of Pro residues in ER by prolyl 4-hydroxylase (P4H) is often a prerequisite for protein O-glycosylation in plants and Hyp-rich glycoproteins (HGRPs), in which O-glycans are added to the hydroxyl group of Hyp, are the most abundant class of Olinked plant glycoproteins. Extensins and arabinogalactan proteins (AGPs) ( Figure 2B ) are the most common members of this group (102) . In plants, O-glycosylation process starts in GA with enzymatic addition of Gal or arabinose (Ara). It can be made on contiguous sequences of Hyp (for example Ser-Hyp 4 ), when short unbranched Ara-oligosacharides are added, or on clustered non-contiguous Hyp sequences that are decorated with branched arabinogalactan polysaccharides, consisting of Gal and Ara (36). Much of the recent work on AGPs has focused on their biosynthesis and several of the biosynthetic glycosyltransferase (GT) enzymes responsible for AG polysaccharide production have been identified (103, 104) and have been grouped into families based on primary structure (http://www.cazy.org/). Wu et al. modifies both the b-1,6-and b-1,3 -galactan present in type II AGP with a biological role during seedling growth (111) . Moreover, Dilokpimol and Geshi (2014) reported the enzyme activities for other two of the Arabidopsis GT14 isoforms, AtGlcAT14B and AtGlcAT14C, which were also found to possess the glucuronosyltransferase activity adding glucuronic acid residues to b-1,3-and b-1,6-linked galactans (112) . Gille et al. (2013) identified one member of the GT-77 family, Reduced Arabinose Yariv1 (RAY1), which seems to catalyze the addition of an arabinosyl residue to a side chain containing multiple arabinosyl residues rather than single arabinosyl residues, and therefore may facilitate the synthesis of an extensinlike module in an AGP (113) two hydroxyproline-O-galactosyltransferases (GALT2 and GALT5), which are members of GT-31 and contain a galectin domain, were identified and it was demonstrated that both enzymes are members of a small multigene family and encode Hyp-GALTs (114, 115) . Moreover, extensive phenotypic characterization of allelic galt2 and galt5 single mutants and galt2galt5 double mutants, which was performed at the biochemical and physiological levels, corroborated the roles of these two enzymes in AG biosynthesis and elucidated the contributions of AG polysaccharides to AGP function. In the recent study, the same group of authors performed the characterization of the remaining GALT members (i.e., GALT1, GALT3, GALT4, and GALT6) of this small six-membered gene family, which are distinguished by encoding a GALT domain as well as a GALECTIN domain (116) . Genetic mutant analysis provided additional in vivo evidence that GALT3, GALT4, and GALT6 function as Hyp-GALTs, similar to GALT2 and GALT5. Allelic galt knock-out mutants for all these genes exhibited reduced Hyp-GALT activity and contained considerably less glycosylated AGPs. Moreover, AGP profiling of the galt3, galt4, and galt6 mutants indicated that their activity is not limited to a particular AGP or a small subset of AGPs, but instead broadly acts on co-expressed AGPs (115) , similar to that previously reported for galt2 and galt5 (116) . Three other hydroxyproline-O-galactosyltransferases (HPGT1-HP-GT3), which are members of GT-31, but lack a galectin domain, were identified by Ogawa-Ohnishi and Matsubayashi (2015) (117) .
O-linked glycosylation in plants was found to have roles in plant growth, development, wound healing and plant-microbe interactions. For example, reagents that bind arabinogalactans have effects on the growth of pollen tube tips, somatic embryogenesis and cell expansion and/or division (118) and probably constitute the plant 'homologues' of animal proteoglycans (119) . However, unlike N-glycosylation, O-glycosylation is not so well understood in plants and its complexity in plant expression systems remains to be completely elucidated. Sequence requirements necessary for conversion of Pro residues of mammalian proteins to Hyp residues by plant P4Hs are not well understood, but studies have shown that plants convert the proline residues to Hyp and attach Ara residues to recombinant proteins (120, 121) . When peptides of mucin 1 glycoprotein (MUC1) were expressed in N. benthamiana, Hyp residues were detected regardless of presence or absence of the O-glycosylation machinery necessary for the transfer of GalNAc (97) . It is still unclear whether the Hyp plant-specific glycosylation and mammalian glycosyltransferases compete for neighboring acceptor sites (97, 121, 122) . Immunological potential of plant-specific O-glycosylation in recombinant proteins is poorly understood, although it has been shown that even a single Ara residue linked to Hyp can constitute an IgE binding epitope and provoke allergic reaction (123) . This suggests that non-human O-glycans can seriously hinder the broad use of plant-made therapeutics and that their removal would be necessary. To accomplish that, additional studies have to be performed and inactivation of plant P4H enzyme would be a first logical step. Namely, in silico analysis of human proteome revealed that 30% of human proteins carry recognition sequence for plant P4H (36), thus representing potential sites for non-human Prohydroxylation on recombinant protein expressed in plant systems. Recently, several members of the A. thaliana P4H family have been characterized (124) , which allows screening for P4H candidates that hydroxylate specific Pro residues on recombinant glycoproteins in order to eliminate them from expression hosts. Such a strategy very likely requires the elimination of several P4Hs with overlapping substrate specificities and due to the possible effects on cell wall assembly (124) it might be necessary to perform tissue-specific knockouts or knockdowns to avoid problems with biomass formation and overall growth of the plants (94) . Besides inactivating P4Hs expression, another approach would be to block hydroxylation of Pro residues using inhibitors. Moriguchi et al. reported that the ferrous chelator 2,2'-dipyridyl, a potent inhibitor of P4Hs, reduced arabinogalactosylation of endogenous proteins in tobacco seedlings (125) . Such a chemical inhibition strategy could be quite useful for transient expression but is less suitable for the stable expression of O-glycosylated recombinant proteins (94) .
Besides having their typical O-glycoslyation on Hypresidues, plants in general miss the machinery for production of mammalian-type O-glycosylation (122). Analysis of recombinant hEPO produced in N. benthamiana plants failed to show any O-linked GalNAc residues (6), thus suggesting that for initiation of mucin-type O-glycan formation, the corresponding mammalian GalNActransferase that transfers a single GalNAc residue to Ser/ Thr residues has to be expressed in plants. Study by Daskalova et al. investigated the possibility of mimicking mammalian O-glycosylation in plants, specifically the mucin-type addition of GalNAc residues (122). Transgenic N. benthamiana plants expressing the human Nacetylgalactosaminyltransferase 2 (GalNAc-T2) enzyme were used, and after enhancing the amount of UDPGalNAc and ensuring its efficient transfer to GA, the majority of model antigen LTB-MUC1 (B subunite of E. coli heat labile toxin fused to human mucin 1 glycoprotein) was glycosylated with GalNAc residues. Efficiency was increased by transforming N. benthamiana line with UDP-GlcNAc 4-epimerase, a UDP-GlcNAc/UDP-GalNAc transporter and the GalNAc-T2 enzymes. However, authors indicate that recombinant protein may also carry Ara-containing plant-specific O-glycans. In a different study performed on N. benthamiana, transient expression of a Pseudomonas aeruginosa Glc(NAc) C4-epimerase and a human polypeptide GalNAc-transferase resulted in GalNAc O-glycosylation of co-expressed human O-glycoprotein substrates (97) Interestingly, plant specific O-glycosylation can be used as a tool for enhancing protein stability (increasing serum half-life of recombinant proteins), by providing resistance to proteolytic degradation in vivo and has been proposed as an alternative to the covalent attachment of polyethylene glycol (PEG) to purified proteins (PEGylation). PEGylation is widely used on number of FDAapproved pharmaceuticals because it increases the molecular mass of the proteins and protects them from proteolytic degradation of endogenous proteases. However, PEGylation has some disadvantages: it is time consuming, can result in increased molecular heterogeneity and can negatively affect activity of recombinant proteins in vivo (128) . In the several studies, Hyp-glycosylation tag (Hyp-Glyco), which consists of repeating sequences of Ser and Pro residues [(SO) n , n=2,10 or 20 and O=Hyp] (129), was fused to recombinant proteins (115, 116) . Substantially greater quantities of proteins, with up to 1400-fold increase in yields, have been reported when the HypGlyco tag was fused with human interferone a2b (hIFN a2b), enhanced green fluorescent protein (EGFP) and human growth hormone (130, 132, 133) expressed in BY2 tobacco and Arabidopsis cell culture. Hydroxylation of Pro residues was limited only to Hyp-Glyco tag with variable arabinogalactosylation of each Hyp residue. When hIFN a2b and human growth hormone were fused with larger tags, (SO) 10, 20 , significant increases in the in vivo serum half-life have been reported (129, 133) . Fusion proteins also retained most of their natural activity, while overall heterogeneity of protein species was significantly lowered compared to heterogeneity following PEGylation (129) . The whole impact of internally located plant-specific O-glycans on the stability and biological activity of recombinant proteins is still under investigation. However, a potential advantage of the addition of plant-specific O-glycans via a protein tag is that they may be removed during downstream processing of proteins (23).
the drawbacks of engineering plant glycosylation pathway on plant development
The absence of any growth phenotype in Arabidopsis cgl1 mutant, which lacks proper N-glycan maturations because of the defect in Golgi localized GnTI (134), laid the foundation for N-glycan engineering of other species like Nicotiana benthamiana and Lemna minor (14, 50) , which extended to the O-glysoylation as well (97, 126, 127) . Majority of these studies reported that in glycoengineered plants no obvious changes in phenotype were observed (14, 50, 11, 127, 90) , thus suggesting that plants tolerate a variety of glycoengineering approaches and are highly convenient for production of glycoproteins with humanized glycosylation (135). However, some new findings indicate that unfavorable phenotypical modifications may appear as a result of stable non-native glycosyltransferases expression in transformed plants (84, 136) . Schneider et al. revealed that N. benthaminana and A. thaliana transgenic plants that stably express a modified version of human b1,4-galactosyltransferase (STGalT) show differences in phenotype (84) . Namely, while some transgenic plants grew normally, other lines exhibited stunted growth and developmental retardation even though no differences were observed between their Nglycosylation profiles. Moreover, recent studies from rice reported adverse phenotypes linked with extensive Nglycan remodeling, thus indicating that glycoengineering in some plant species might require new strategies and implementation of more elaborate tools (136). These findings should be taken into consideration in respect to stable glycan engineering in plants and further studies are necessary to investigate in detail the consequences on growth, development, reproduction and stress response of stable engineered plants that carry human-type complex N-glycan modifications.
conclusIons
It is now becoming apparent that plants and methods of plant molecular farming offer a powerful expression platform for the production of a variety of recombinant proteins, which show similar, or even higher, biological activity then protein or native homologs in cultured mammalian cells currently used for large-scale production. Substantial achievement has been made in production of plant-made glycoproteins using glycoengineered plant expression systems. As our understanding of structural and functional implications of diverse PTMs increases, we can assume that development of safer and more efficient next-generation biotherapeutics, with optimized glycoforms, will also improve in years to come. Approaches aiming to engineer plant-produced recombinant proteins with enhanced pharmacological properties, although in its infancy, show significant promise. However, the drawbacks of methods applied for engineering plant glycosylation pathway on plant development should also be considered in further studies.
